Vosoritide

What it's for

Vosoritide is a modified C-type natriuretic peptide analog resistant to neutral endopeptidase. It increases linear growth in children with achondroplasia and open growth plates as labeled.

What it does for the body

It increases linear growth in children with achondroplasia and open growth plates as labeled. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.

What it targets

NPR-B (NPR2) activation antagonizes overactive FGFR3 signaling that impairs cartilage cell proliferation in achondroplasia. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.

Research context

Bottom line for readers: Vosoritide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.

Studied for (literature interest)

• Bones research interest (educational tag)

Cautions (educational)

• Educational only — not medical advice.
• DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

• FDA search: Vosoritide — FDA.gov search
• ClinicalTrials.gov search: Vosoritide — U.S. clinical trials registry
• Drugs@FDA search: Vosoritide — FDA drug database (if approved)
• PubMed search: Vosoritide — NCBI PubMed
• PubMed Central search: Vosoritide — NCBI PMC

Reference

No ref on file.